Novo Nordisk A/S (NVO)
Coverage summary
Aardvark Labs Capital Research has covered Novo Nordisk A/S (NVO) since May 7, 2026. The company is in the Healthcare sector. This page lists 3 reports: 3 earnings recaps.
The latest is the Q3 2026 Earnings Recap, published November 5, 2026. The current rating is Hold, the same in every report since coverage began.
Translations: 2 in Chinese.
All NVO reports
2026-11-05
Recap: Q3 2026
Third Raise, First Narrowing of the US Obesity Gap, and a Medicare Bridge That Expires in 2027
2026-08-05
Recap: Q2 2026
Guidance Up Six Points, Stock Down Six Percent: The Pill Works, US Wegovy Injectable Falls 22%
2026-05-07
Recap: Q1 2026
Wegovy Pill Sets a Launch Record, and Novo Still Under-Grew an 85% US Obesity Market